Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02330094 · ClinicalTrials.gov registry record · Phase 4
Gabapentin for Headache in Aneurysmal Subarachnoid Hemorrhage
A Phase 4 study of Aneurysmal Subarachnoid Hemorrhage, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 4
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT02330094 is a Phase 4 study of Aneurysmal Subarachnoid Hemorrhage that has completed, run by Mayo Clinic. The registered enrollment target is 16 participants, below the 345-participant average among 4 other Aneurysmal Subarachnoid Hemorrhage trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02330094, a Phase 4 study of Aneurysmal Subarachnoid Hemorrhage, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to see how much gabapentin will reduce headaches associated with subarachnoid hemorrhage (SAH) and to reduce the amount of narcotic pain medication prescribed.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Gabapentin
Study Locations (1)
Florida
- Mayo Clinic in Florida - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2014-12 |
| Est. Completion | 2017-09-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02330094
The ClinicalTrials.gov registry entry for NCT02330094 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 345-participant average among 4 other Aneurysmal Subarachnoid Hemorrhage trials with a reported enrollment target (95% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Aneurysmal Subarachnoid Hemorrhage appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02330094 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT02330094 about?
NCT02330094 is a clinical study titled "Gabapentin for Headache in Aneurysmal Subarachnoid Hemorrhage". The purpose of this study is to see how much gabapentin will reduce headaches associated with subarachnoid hemorrhage (SAH) and to reduce the amount of narcotic pain medication prescribed.
What is the current status of trial NCT02330094?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 16 participants. The study started on 2014-12. Estimated completion is 2017-09-01.
What conditions does trial NCT02330094 study?
This clinical trial studies the following conditions: Aneurysmal Subarachnoid Hemorrhage.
What interventions are being tested in trial NCT02330094?
The interventions under investigation include: Placebo (DRUG), Gabapentin (DRUG).
Who is sponsoring clinical trial NCT02330094?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02330094 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Aneurysmal Subarachnoid Hemorrhage
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Deferoxamine In the Treatment of Aneurysmal Subarachnoid Hemorrhage (aSAH)
RECRUITING · Phase 2
-
Tocilizumab-aazg for Hemorrhage: Reduction of Ischemic Vascular Events
RECRUITING · Phase 1
-
Florida Cerebrovascular Disease Biorepository and Genomics Center
ACTIVE NOT RECRUITING
-
Clazosentan in Reducing Vasospasm-related Morbidity and All-cause Mortality in Adult Patients With Aneurysmal Subarachnoid Hemorrhage Treated by Surgical Clipping
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.